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Abstract
Background: Although there have been dramatic strides made recently in the treatment of chronic hepatitis C
virus infection, interferon-α based therapy remains challenging for certain populations, including those with
unfavorable IL28B genotypes, psychiatric co-morbidity, HIV co-infection, and decompensated liver disease. We have
recently shown that ATIII, a serine protease inhibitor (serpin), has broad antiviral properties.
Results: We now show that ATIII is capable of inhibiting HCV in the OR6 replicon model at micromolar
concentrations. At a mechanistic level using gene-expression arrays, we found that ATIII treatment down-regulated
multiple host cell signal transduction factors involved in the pathogenesis of cirrhosis and hepatocellular carcinoma,
including Jun, Myc and BMP2. Using a protein interactive network analysis we found that changes in
gene-expression caused by ATIII were dependent on three nodes previously implicated in HCV disease progression
or HCV replication: NFκB, P38 MAPK, and ERK1/2.
Conclusions: Our findings suggest that ATIII stimulates a novel innate antiviral host cell defense different from
current treatment options.
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Background
Antiviral treatment of hepatitis C virus (HCV) is aimed
at persistent eradication of the virus, as measured in sus-
tained virological response (SVR). SVR rates are high
with current treatment options, a combination of peg-
interferon-apha (IFN-α)–ribavirin and direct-acting anti-
viral agent (DAA) but HCV patients infected with HIV
and/or other co-morbidities might benefit less from the
new treatment options [1].
HCV infection is currently one of the most clinically
relevant co-morbidities in the HIV population; it affects
15–30% of the 1 million HIV-positive patients in the US
[2]. Furthermore, progression to end-stage liver disease
occurs six times faster in co-infected patients [3-6], with
decompensated cirrhosis being one of the primary causes
of hospitalization and death in this population [4,6-8].
Treatment of HCV infection in HIV-positive patients has
a lower success rate [9-13] and an increased risk of hep-
atotoxicity from antiretroviral drugs compared to HIV-
negative patients [14-16]. Because of an increased risk of
life-threatening complications during peg-IFN-α–ribavirin
therapy, patients with hepatic decompensation are not
typically candidates for this therapy unless easy access to
orthotopic liver transplantation is available [17,18]. Fur-
thermore, since the antiviral activity of IFN-α is mediated,
at least in part, through the cytokine network, immuno-
logical abnormalities, such as those that often result from
HIV infection, reduce IFN-α efficacy. This loss of efficacy
has the result of higher treatment failure in HIV/HCV
coinfected patients when compared to HCV monoinfected
patients [19-22].
The effective treatment of HIV in persons with
advanced cirrhosis may be challenging due to cirrhosis-
induced alterations in the hepatic metabolism of anti-
retroviral drugs and the potential for increased risk of
drug-induced liver injury. To prevent possible liver tox-
icity, drug doses may be reduced and certain otherwise
preferred drugs may be avoided [23,24]. Reducing anti-
retroviral doses and hence plasma concentrations, how-
ever, may also lower the barrier to the emergence of
drug-resistant HIV. Thus, effective therapy to eliminate
HCV is necessary to optimize therapy for HIV.
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member of the serine protease inhibitor protein family
(serpins), as its anti-inflammatory and anticoagulant activ-
ities were found to decrease liver damage [25]. Serpins
participate in the early innate immune response to viral
infection [26] and they simultaneously possess broad-
spectrum anti-viral and anti-inflammatory capabilities. In
the case of HIV infection, serpins reportedly interfere with
viral replication at both the entry and the reverse tran-
scription stages [27-30]. In particular, the serpins alpha-1
anti-trypsin, the secretory leukocyte protease inhibitor and
ATIII have significant in vitro ability to inhibit HIV-1, with
the latter, ATIII, being the most potent [29-34].
In HCV infections with co-morbidities new drugs with
different mechanisms of action other than the DAAs are
urgently needed. We hypothesized that the broad immu-
nomodulatory and anti-viral properties of ATIII might
extend to other chronic viral infections due to a different
mechanism of action, in particular, since a serpin recep-
tor, the LDL receptor-related protein 1 (LRP1), is highly
expressed on hepatocytes [34] and was found to block
HCV infection [35].
Therefore, we undertook an investigation of whether
ATIII has the potential to inhibit HCV replication
in vitro. We used gene-arrays to probe the molecular
mechanisms underlying ATIII’s immunomodulatory and
antiviral properties, and uncover the signal transduction
pathways that result in inhibition of viral replication.
Results
ATIII treatment augments the inhibition of HCV
replication by IFN-α
IFN-α is currently part of the standard therapy for
chronic HCV infection, in addition to ribavirin and an
NS3-4A protease inhibitor. In certain patient subpopula-
tions, this regimen is not always effective or is poorly
tolerated. We have previously reported that the serpin
ATIII has potent anti-viral activity against HIV [33,34].
We sought to determine whether ATIII might also have
activity against HCV since serpin receptors are highly
expressed on hepatocytes [36]. We employed the OR6
replicon system [37] expressing full-length genotype 1b
virus to assess whether ATIII is capable of inhibiting
HCV [38,39]. Although heparin activation augments the
anti-HIV activity of ATIII we used unmodified ATIII be-
cause heparin activation also increases the off-target
effects of ATIII on thrombin. Unmodified ATIII has a
demonstrated favorable toxicity profile and has been
used in humans for more than 20 years.
We initially explored the effect of ATIII monotherapy
on HCV replication. We treated OR6 replicon cells with
7, 17 and 58 μM of ATIII for 48 h. We had previously
demonstrated that these concentrations effectively inhib-
ited HIV replication in vitro [40]. We quantified viral in-
hibition as the percentage of residual luciferase activity
compared to a vehicle treated control. We observed that
ATIII monotherapy inhibited HCV replication in the
replicon system in a dose dependent manner, with the
lowest dose of 7 μM inhibiting virus 70.2% ±8.8%
(p<0.001, n=6) (Figure 1A).
For comparison, we assessed the ability of IFN-α2
monotherapy to inhibit the replicon. We tested doses of
4 and 16 IU IFN-α2, and found 71.4±10.1% and 84.4
±8.4% inhibition of HCV, respectively. These results are
similar to what has been reported previously [41]. We
next sought to determine whether ATIII and IFN-α
might have an additive effect on HCV replication. We
treated replicon cells with 7, 17 and 58 μM ATIII and
with 4 and 16 IU/ml IFN-α2 (Figure 1B/C). We
observed an additive effect, as treatment with ATIII sig-
nificantly decreased HCV replication compared to IFN-
α2 monotherapy (P-value of between <0.05 and <0.01).
Figure 1 Additive effect of simultaneous ATIII and IFN-α treatment on HCV replication. (A) Effect of ATIII treatment alone on HCV
replication. Significant inhibition is indicated as asteriks in compare to vehicle treated control (***, P<0.001, one-table T-test, n=6). (B) Additive
effect of ATIII on 4 IU/ml IFN-α2 treatment (n=3). (C) Additive effect of ATIII on 16 IU/ml IFN-α2 treatment (n=3). Luciferase expression in HCV OR6
replicon cells was used as an indicator of HCV replication after treatment with IFN-α2 and/or ATIII. 5x10
4 HCV OR6 replicon cells were treated with
different concentrations of IFN-α2 and ATIII. Residual luciferase activity as percentage of the vehicle treated control was used to quantify HCV
replication. The additive effect of ATIII (7, 17, 58 μM) on different concentrations of IFN-α2 (in B and C) is shown by significant decrease (*, P<0,05;
**, P<0.01; *** P<0.001, unpaired T-test) in residual luciferase activity in compare to inhibition of IFN-α2 starting concentration (4, 16 IU/ml
without ATIII treatment). Error bars represent standard error of the mean.
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dose (7 μM) of ATIII tested (Figure 1). We performed
similar experiments using IFN-α5, a different subtype of
IFN-α, and confirmed the additive effects of ATIII
observed with IFN-α2 (data not shown).
To exclude the possibility that the antiviral effect of
ATIII was due to a cytotoxic effect, we assayed for cyto-
toxicity using Neutral Red and Trypan Blue exclusion
staining at the indicated concentrations of drugs.
Neither ATIII alone or in combination with IFN-α2o r
IFN-α5 showed a cytotoxic effect (data not shown).
ATIII-induced alterations in gene expression in non-
replicon cells
To assess the effect of ATIII treatment on host cell gene
expression in the absence of HCV protein expression,
we treated Huh7.5. non-replicon cells with the highest
concentration of ATIII that would be used in the subse-
quent gene array experiments: 24 U/ml (58 μM), which
is 24-fold the physiologic concentration. We found no
significant alterations in expression of genes in the array
following ATIII treatment of the non-OR6 replicon cells,
demonstrating that, at these concentrations and in the
absence of HCV replication, ATIII has no significant ef-
fect on expression of our transcriptional pathways of
interest. Using Trypan Blue exclusion staining we also
found no drug-related cytotoxicity at the concentrations
used (data not shown).
HCV-induced alterations of hepatocyte gene expression
To assess the effect of HCV replication on hepatocyte
physiology we compared the transcriptional profile of
HCV replicon cells to that of Huh7.5 non-replicon cells
using the Transduction Pathfinder RT2 Profiler PCR
Assay. Initially, experiments were performed in the
absence of exogenous ATIII. We observed substantial
differences in the transcription of multiple genes
involved in the innate host cell response between cells
expressing and not-expressing HCV (Tab. I). Many of
these HCV-induced changes have been previously
described elsewhere [42-49] confirming the validity of
our system. The gene with the greatest increase in ex-
pression was Matrix Metallopeptidase 10 (MMP10) (49-
fold, P = 0.006), a key mediator in the Jak-Stat pathway
and part of the inflammatory response of the host cell
against HCV. Additional effects of HCV on host gene
expression include activation of p53 and TGF-β path-
ways: we found a 3-fold (P = 0.03) increase of Cyclin-
dependent kinase inhibitor (CDKN) 1A and a 10-fold
(P = 0.005) increase of CDKN2B. Other observations
from this study that are consistent with previously
described associations with HCV include findings of a
9-fold (P = 0.04) increase of Bone morphogenetic protein
4 (BMP4), part of the hedgehog pathway, and a 4-fold
(P = 0.03) increase in Heat Shock Protein (HSP) 90AA2,
part of the cellular stress response.
Effect of ATIII on HCV-induced changes in gene
expression
We subsequently sought to determine if ATIII might
modulate the effects of HCV on host gene expression.
We treated replicon cells with 7 μM ATIII, a concentra-
tion at which inhibition of HCV replication was
observed, and compared gene expression to untreated
replicon cells (Table 1). None of the genes affected by
HCV expression appeared to be substantially affected by
ATIII treatment at this lowest dose.
At higher concentrations of ATIII, we found only a
modest effect on HCV-induced transcriptional changes
(data not shown). There was no ATIII dose-dependent
Table 1 Determination of ATIII treatment effect on gene expression in the context of HCV
Gene Symbol Replicon/Non-replicon
Gene expression
Replicon/Replicon+7 μM
ATIII Gene expression
Fold change P-value Fold change P-value
Bone morphogenetic protein 4 BMP4 9.15 0.04 −1.68 0.09
Cyclin-dependent kinase inhibitor 1A CDKN1A 2.61 0.03 −1.64 0.1
Cyclin-dependent kinase inhibitor 2B CDKN2B 10.98 0.005 −1.59 0.1
Cytochrome P450, family 19, subfamily A, polypeptide 1 CYP19A1 5.70 0.002 −1.73 0.01
Fatty acid synthase FASN 4.01 0.01 −2.87 0.9
Heat shock 27kDa protein 1 HSPB1 2.82 0.001 −1.21 0.6
Heat shock protein 90kDa alpha class A member 2 HSP90AA2 4.01 0.03 −1.14 0.6
Interleukin 4 receptor IL4R 4.76 0.01 −1.79 0.04
Matrix metallopeptidase 10 MMP10 49.29 0.006 −2.19 0.3
Ornithine decarboxylase 1 ODC1 4.49 0.01 1.35 0.4
Retinol binding protein 1 RBP1 2.66 0.045 −1.59 0.2
WNT1 inducible signaling pathway protein 1 WISP1 6.32 0.008 −1.16 0.6
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results suggest that the mechanism by which ATIII inhi-
bits HCV within 48 h may not involve modulation of
the genes influenced by HCV infection.
ATIII-induced alterations in replicon cell gene expression
HCV infection often leads to chronic hepatitis, cirrhosis,
and occasionally to hepatocellular carcinoma [50]. This
progression in liver pathology is associated with
increased expression in hepatocytes of the transcription
factors JUN and MYC, which may play crucial roles in
oncogenesis [51,52]. In order to investigate the influence
of ATIII on pathways important for HCV disease pro-
gression we employed the Transduction Pathfinder RT2
Profiler PCR Assay to quantify the expression of 84 key
genes belonging to 18 different regulatory pathways in
the presence of different concentrations of ATIII.
To investigate whether the therapeutic use of ATIII
might have an influence on gene-expression in OR6 rep-
licon cells, we treated these cells with supra-physiologic
concentration of ATIII: 2.4-fold (7 μM), 7-fold (17 μM)
and 24-fold (58 μM) blood concentrations. We used
supra-physiologic doses of ATIII in part because ATIII is
known to accumulate in the liver - a fact which may be
of therapeutic advantage.
Treatment of replicon cells with these doses of ATIIII
altered expression by more than 5-fold in a group of
genes when compared to vehicle treated controls
(Figure 2). Interestingly, genes that were most signifi-
cantly affected were all down-regulated. Among those
genes found to be down-regulated following ATIII treat-
ment were JUN and MYC, which are known to be im-
portant factors in the pathogenesis of HCV-related
hepatocellular carcinoma. We found that these genes
were down-regulated in a dose dependent manner, up to
931-fold for JUN (P = 0.0002), and up to 45-fold for
MYC (P = 0.0007) at 58 μM.
The next largest decrease in gene expression, up to 346-
fold (P = 0.009 at 58 μM), was observed for the transcrip-
tion factor CAAT/enhancer binding protein (CEBPB), a
protein regulated by insulin. Another gene downstream of
insulin Hexokinase 2 (HK2), was down-regulated up to
14-fold (P = 0.0039). Growth arrest and DNA-damage-
inducible protein (GADD45A), a gene in the p53 pathway,
was down-regulated 35-fold at 58 μM (P = 0.0023). Bone
morphogenetic protein 2 (BMP2), a gene of the Hedgehog
pathway, was down-regulated 13-fold (P = 0.03) at 58 μM.
B-cell CLL/lymphoma2-like 1 (BCL2L), a transcript
belonging to the Jak/Src pathway, exhibited an approxi-
mately 10-fold decrease in expression (Figure 2). Down-
regulation of these genes was specific to ATIII treated
OR6 cells with ongoing HCV replication, and was not
observed in the untreated OR6 replicon, nor in the ATIII-
treated Huh7.5 controls suggesting that ATIII induces a
specific anti-viral gene program.
Changes in gene expression when ATIII is used in
combination with IFN-α
Our data indicate that both IFN-α and ATIII stimulate
the host innate antiviral response. We sought to deter-
mine whether these proteins engaged redundant cellular
pathways, or had non-overlapping mechanisms of action.
We applied IFN-α2 in isolation, to measure the gene ex-
pression alterations attributable to this drug. The gene
expression profile induced by IFN-α monotherapy that
we observed was consistent with previous reports
[53,54]. At 4 IU/ml, we found Interferon regulatory fac-
tor 1 (IRF-1) up-regulated 2-fold. We also identified a
set of inflammatory genes that were down-regulated:
Colony stimulating factor 2 (CSF2) (inhibited 11.5-fold,
P=0.01), IL-1α (inhibited 4-fold, P=0.02), MMP7 (inhib-
ited 6-fold, P=0.04), MMP10 (inhibited 3-fold), Nitric
oxide synthase 2A (NOS2A) (inhibited 9-fold, P=0.009),
and Prostaglandin-endoperoxide synthase (PTGS2) (5-
fold, P=0.01) (Figure 3).
When IFN-α was administered in combination with
ATIII, additional genes were significantly altered, poten-
tially explaining the additive antiviral effect of ATIII
when added to IFN-α treatment. The most substantially
down-regulated gene was BMP2, belonging to the
Hedgehog pathway, which was decreased by 37-fold
(P=0.04). JUN and PTGS2 both belonging to the
Phospholipase C pathway were 14-fold (P=0.08) and 9-
fold (P=0.02) down-regulated. CEBPB of the insulin
pathway was 8-fold down-regulated (Figure 3).
Figure 2 Key signal transduction pathfinder genes altered after
ATIII treatment of HCV OR6 replicon. Analysis of activated signal
transduction pathways in HCV OR6 replicon cells after treatment
with ATIII. 5x10
4 HCV OR6 replicon cells were treated with 7, 17, 58
μM ATIII for 48 h. A real-time PCR expression array was used to
analyze the expression of 84 key genes from 18 signal transduction
pathways. Asterisks show genes with significant changes (*, P<0,05;
**, P<0.01; *** P<0.001) in gene expression compared to vehicle
control as calculated by the ΔΔCt method of three independent
experiments are shown. All genes are normalized using the GAPDH
house-keeping gene. Only genes with more than a 5-fold change in
gene-expression are shown.
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clude the possibility that our results may have been idio-
syncratic to IFN-α2. We observed the same gene
expression pattern with IFN-α5 treatment, with or with-
out ATIII treatment (data not shown).
Network analysis of ATIII-induced interactomes in OR6
replicon cells
To gain further insight into the mechanism of action of
ATIII in reducing HCV replication, we performed a bio-
logic network analysis of ATIII treated OR6 replicons.
This analysis method complements data generated from
our gene arrays by facilitating the recognition of hier-
archical gene clusters that might intersect with HCV
replication. This software-supported interactome ana-
lysis is based on a vast library of gene interactions
known to regulate certain pathways and allows to iden-
tify pathways effected by a drug.
We used genes which we had observed to be signifi-
cantly up-regulated by HCV replication (Table 1) to gen-
erate interactomes describing host cell transduction
pathways activated by HCV. We identified nodules regu-
lated by ERKs, AKT, PI3K, RAS, NFκB, P38, P38 MAPK
and MAPK as all being activated by HCV infection
(Figure 4A). We then assessed the influence of treatment
with the high dose (58 μM) of ATIII on gene expression
to determine which of these HCV nodules were affected
by gene expression changes downstream of ATIII. We
found that ATIII interacted with two independent net-
works that were also modulated by HCV. The highest
scoring network was mostly dependent on the ERKs
(Figure 4B), and the second highest scoring network
interfered with NFκB and P38 MAPK (Figure 4C). These
results suggested that despite our observation that ATIII
and HCV alter the expression of different sets of individ-
ual genes, transcriptional programs activated by ATIII
may interfere with 3 out of the 6 nodules activated by
HCV. We hypothesize that this might be significant
enough to counteract some of the pathologic effects of
HCV.
We have demonstrated additive activity of IFN-α and
ATIII in inhibiting HCV. We thus next sought to deter-
mine whether they might exhibit overlapping effects on
the HCV interactome. We compared the effect of IFN-
α/low ATIII dose therapy to that of IFN-α alone on
HCV induced nodules. Treatment with 4 IU/ml IFN-α
alone altered three HCV induced nodules: P38 MAPK,
MAPK and NFκB (Figure 4D). The addition of low dose
ATIII did not alter the number of nodules affected, but
did increase the IRF1 response (Figure 4E) which is
known to be responsible for some of the HCV inhibition
and might be the reason for the additive effect on IFN-α
treatment.
Discussion
The cornerstone of effective therapy for chronic hepatitis
C infection has been IFN-α, a critical mediator in the in-
nate immune response to viral infection. Even with the ad-
vent of small molecule direct inhibitors of viral enzymatic
activity, IFN-α remains important for attaining sustained
virologic response, perhaps because of the need to engage
host antiviral programs to completely eradicate viral reser-
voirs. However, interferon-based therapy is not without its
shortcomings, including poor tolerability or poor efficacy
in certain patient populations.
We now demonstrate that a novel activator of host in-
nate antiviral responses, ATIII, may give insight into ad-
junctive therapies for HCV that might augment or even
replace IFN-α in cases where there are co-morbidities or
genetic factors that preclude the use of IFN-α. There is
Figure 3 Down-regulation of key signal transduction pathway
genes in HCV OR6 replicon after treatment with IFN-α and
ATIII. 5x10
4 HCV OR6 replicon cells were treated with 7 μM ATIII/ml
and 4 IU/ml IFN-α for 48 h, and RNA was purified. A real-time RT-
PCR expression array was used to analyze the expression of 84 key
genes from 18 signal transduction pathways. Genes with significant
changes (*, P<0.05), in gene expression compared to vehicle control
as calculated by the ΔΔCt method of three independent
experiments are shown. All genes are normalized using the GAPDH
house-keeping gene. Only genes with more than a 2-fold change in
gene-expression are shown.
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pathogenesis of HCV infection: low plasma concentrations
of ATIII have previously been correlated with progression
to chronic hepatitis and cirrhosis [55]. Furthermore, there
is a high density of serpin receptors on hepatocytes, sug-
gesting that serpins may have localized effects on hepatic
innate immunity [56].
We used the OR6 replicon to probe how ATIII might
influence HCV pathogenesis. We demonstrated that
ATIII inhibited HCV replication at micromolar concen-
trations. While this inhibition was not as potent as that
of either IFN-α or fluvastatin [41] it was many-fold
greater than that of ribavirin [57].
We next investigated the mechanism of ATIII’sa n t i -
HCV activity. After more than 20 years of research, the
mechanism of action of IFN-α in inhibiting HCV has only
recently been determined. HCV cell-based expression
models, as the one used in this study, were used to dem-
onstrate that IFN-α-induced signal transduction through
the Jak/STAT pathway was necessary for HCV inhibition
[45]. To elucidate the mechanism(s) through which ser-
pins activate the host defense system, we employed the
OR6 replicon system, and analyzed changes in gene-
expression patterns of 84 key genes representative of 18
different signal transduction pathways. We found that
ATIII treatment down-regulated JUN expression. It has
previously been shown that the JNK inhibitor, SP600125,
interferes with the oncogenic potential of HCV non-
structural protein 3 [58]. In addition, we found that ATIII
treatment reduced induction of the transcription factor
MYC, expression of which has been associated with pro-
gression of liver disease to chronic hepatitis, cirrhosis, and
Figure 4 Interactive network analysis of HCV, ATIII and IFN-α altered hepatocyte genes. (A) Network with nodules and significant genes
altered by HCV. (B and C) Two highest scoring network (out of three) with nodules affecting genes activated by high dose (58 μM) ATIII
treatment of the HCV replicon. (D) Network with nodules and significant altered genes after IFN-α treatment of the HCV replicon. (E) Network
with nodules and significant altered genes after IFN-α and low dose (7 μM) ATIII treatment of the HCV replicon. Pathway analysis was done using
Ingenuity Pathways Analysis Software with significant (P<0.05) up-regulated (red) and down-regulated (green) genes indicated. Nodules (double
circles) are genes with a reported influence on genes altered by HCV, ATIII or IFN-α. Significance was calculated using the ΔΔCt method for three
independent experiments.
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reduced CEBPB, a transcription factor of the CCAAT/
enhancer-binding protein class. These transcription
factor proteins have been shown to be important for
HCV inhibition: the CCAAT/enhancer-binding protein-
homologous protein (CHOP) is activated by HCV enve-
lope protein and is associated with disease progression
[60]. The mechanism of action of this protein class is not
fully understood, but CHOP can sensitize cells to apop-
tosis by down-regulation of BCL-2 expression, depletion
of cellular glutathione, and exaggerated production of
reactive oxygen species [61].
Our data also identified a substantial down-regulation
of BMP2, a protein that regulates hepcidin [62]. Hepci-
din is critical for iron homeostasis and is also a critical
host cofactor involved in promoting HCV replication
[63]. Chronic HCV infection has been found to be asso-
ciated with increased serum iron and transferrin satur-
ation as well as hepatic iron accumulation; moreover,
hepatic hepcidin mRNA expression is increased in
patients with chronic HCV infection [64]. Hepcidin
transcription is stimulated by iron overload as well as by
inflammation through IL-6 [65], which is elevated in
patients with chronic HCV. The identification of hepci-
din as a HCV replication cofactor suggests a molecular
basis for the well-known clinical association between
chronic HCV infection and dysregulation of iron
homeostasis. Moreover, it is possible that the up-
regulation of hepcidin transcription by IL-6 potentially
creates a positive feedback loop between chronic inflam-
mation and HCV replication. Together, these findings
suggest that ATIII therapy may reduce the pathogenic
impact of HCV infection.
Thus, our data indicate that ATIII targets several
genes that are known to promote both liver disease and
HCV replication. ATIII treatment may therefore alter
the expression of these genes and act to simultaneously
slow both HCV replication and ultimately liver degener-
ation. ATIII’s effect on gene-expression was also
observed when replicon cells were co-treated with low
concentrations of IFN-α. It was during this dual drug
treatment that gene expression of BMP2, CEBPB, and
JUN were most dramatically down-regulated.
Protein interactive network analysis demonstrated that
the genes that were altered by ATIII treatment were
dependent on three nodes: NFκB, P38 MAPK and the
ERKs. All of these nodes have been described previously
as having a role in HCV replication and HCV-related
liver disease [47,66-69] confirming ATIII’s potential to
limit HCV’s destruction of the liver. These nodules are
also affected in ATIII-mediated inhibition of HIV [40].
Although our replicon model can facilitate identification
of substances that affect either viral genomic replication
or host cell factors involved in viral genomic replication, it
cannot be used to identify substances that alter other
stages of the viral life cycle. Therefore, future studies using
fully infectious, cell-culture-adapted HCV strains will be
required to study other aspects of the HCV life cycle, such
as viral entry, uncoating, viron assembly and secretion.
Our data identified several genes altered by ATIII that
were previously shown to be correlated with HCV disease
outcome. This might explain the additive therapeutic ef-
fect when ATIII was used in combination with IFN-α.W e
further found that ATIII’s mechanism of action is most
likely multi-faceted, warranting further research into each
distinct signaling pathway.
Material and methods
Cell culture
OR6 replicon cells were a gift from Dr. Nobuyuki Kato
(Okayama University, Japan) and were propagated in
Dulbecco’s Modified Eagle’s medium (DMEM) contain-
ing 10% fetal bovine serum (FBS) supplemented with
1% penicillin-streptomycin, and 500 μg/ml Geneticin
(Invitrogen Corp., Carlsbad, CA). Cells were cultured in
a 37°C, 5% CO2-humidified incubator for all experi-
ments. To decrease day-to-day variability in the assay,
a large homogenous population of subconfluent cells
was passaged so that a similar lot of cells could be used
throughout the assay.
Protein reagents
Clinical grade human ATIII (Talecris, Durham, NC) had a
concentration of 6 U/mg and a purity >98%. For ATIII
drug combination experiments, recombinant human IFN-
α2 and IFN-α5 (PBL Interferon Source, Piscataway, NJ)
was used, which had a concentration of 2.38 x 10
8 and
2.33 x 10
8 units/mg, respectively, and a purity of > 98%.
Determination of inhibitory potency
HCV replication inhibition was determined as the per-
centage of luciferase activity retained by the OR6 repli-
con after ATIII treatment, compared to a vehicle-treated
control [37]. Luciferase activity was measured using the
Renilla Luciferase Assay System (Promega, Madison,
WI) at 1 sec. intervals using the 1420 Multilabel Counter
Victor 3 (PerkinElmer, Waltham, MA). Cell viability was
assessed using Neutral Red staining and Tryphan Blue
exclusion staining.
Signal transduction pathway profiling
OR6 replicon cells were harvested after 48 h of ATIII
and/or IFN-α treatment and total RNA was recovered
using the RNeasy Kit (Qiagen) with an on-column
DNAse digest (Qiagen) according to the manufacturer’s
protocol. Approximately 100 ng RNA was used for
cDNA synthesis using the SuperArray RT
2 First Strand
Kit (SABiosciences, Frederick, MD, cat. no. C-03). cDNA
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2 Profiler PCR Array Human Signal
Transduction PathwayFinder (SABiosciences, cat. no.
PAHS-014A). The genes that were investigated can be
found at http://www.sabiosciences.com/rt_pcr_product/
HTML/PAHS-014A.html. Three arrays of three inde-
pendent experiments were performed for each treatment
condition. Relative levels of transcription were deter-
mined by using the ΔCt values for each gene obtained by
subtracting the mean threshold cycle (Ct) of the GAPDH
housekeeping gene from the Ct value of the gene of
interest. The average ΔCt value for 3 experiments was
calculated, for each gene of interest, and the average
normalized transcription was calculated as follows:
2( −averageΔCt)
-1. Fold increases of gene transcription,
before and after treatment was calculated by dividing the
average normalized transcription of each gene in the test
sample by the corresponding control. Statistical signifi-
cance in up- or down-regulation of transcription was
determined by Student T-test (2-sample, equal variance,
2-tailed distribution), comparing the ΔΔCt (ΔΔCt = ΔCt
treated - ΔΔCt control). Significant differences were
identified when P was less than 0.05.
Analysis of protein interactive networks and statistical
analysis
Functional analysis of interacting proteins was deter-
mined using a commercial System Biology package, In-
genuity Pathways Analysis (IPA 8.0) (www.ingenuity.
com) following the application protocols.
Statistical analysis
The statistical significance of differences between groups
was determined using the program GraphPad Prism. A
P value of <0.05 was considered statistically significant.
Statistical analysis was performed using one table T-test
or the unpaired T-test. Error bars represent standard
error of the mean (S. E.).
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